Anamorelin, as a new, oral, selective ghrelin receptor agonist, was launched in Japan in April 2021 for the treatment of cancer cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, colorectal cancer and other malignant tumors.
Clinical data shows that anamolin has the effect of increasing weight, muscle mass, and appetite in cancer cachexia patients.
Anamorelin is the first drug specifically for the treatment of cachexia launched in Japan in 2021, which stimulates appetite by mimicking ghrelin; As a ghrelin receptor agonist, it···【more】
Article source:Lucius LaosRelease date:2024-08-20Recommended:99
Anamoreline is the world's first drug for the treatment of cancer cachexia, which was launched in Japan in 2021; By activating ghrelin receptors, it increases appetite and prom···【more】
Article source:Lucius LaosRelease date:2024-08-19Recommended:108
Anamorelin, a drug that specializes in the treatment of cancer cachexia, was launched in Japan in 2021. Anamorelin helps patients increase their appetite and weight by mimicking th···【more】
Article source:Lucius LaosRelease date:2024-08-19Recommended:106
Through its distinctive mechanism of action, Anamorelin presents novel therapeutic modalities for individuals afflicted by cachexia, thereby enhancing their nutritional state and e···【more】
Article source:Lucius LaosRelease date:2024-08-05Recommended:109
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: